[1] Iglesias-Bartolome R, Gutkind JS. Unleashing immunotherapy by targeting cancer stem cells [J]. Cell Stem Cell, 2020, 27(2):187-189. [2] Almangush A, Heikkinen I, Mäkitie AA, et al. Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis [J]. Br J Cancer, 2017, 117(6):856-866. [3] Li G, Yang T, Chen Y, et al. USP5 sustains the proliferation of glioblastoma through stabilization of cyclin D1 [J]. Front Pharmacol, 2021, 12:720307. [4] Li Y, Wang Y, Li J, et al. Tacrolimus inhibits oral carcinogenesis through cell cycle control [J]. Biomed Pharmacother, 2021, 139:111545. [5] Hao J, Zhang W, Lyu Y, et al. Combined use of cyclinD1 and Ki67 for prognosis of luminal-like breast cancer patients[J]. Front Oncol, 2021, 11:737794. [6] El-Gendi S, Abu-Sheasha G. Ki-67 and cell cycle regulators p53, p63 and cyclin D1 as prognostic markers for recurrence/ progression of bladder urothelial carcinoma [J]. Pathol Oncol Res, 2018, 24(2):309-322. [7] Lugli A, Zlobec I, Berger MD, et al. Tumour budding in solid cancers [J]. Nat Rev Clin Oncol, 2021, 18(2):101-115. [8] Zhao Y, Fu X, Lopez JI, et al. Selection of metastasis competent subclones in the tumour interior [J]. Nat Ecol Evol, 2021, 5(7):1033-1045. [9] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3):209-249. [10] Lassen P, Lacas B, Pignon JP, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project [J]. Radiother Oncol, 2018, 126(1):107-115. [11] Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer [J]. Nat Rev Cancer, 2018, 18(5):269-282. |